ℹ️
🇨🇿
Hledání
Hledat publikace relevantní k dotazu "AKR1C3"
AKR1C3
Publikace
Předměty
Osoby
Publikace
Studium
publication
Isoquinoline alkaloids as a novel type of AKR1C3 inhibitors
2014 |
Farmaceutická fakulta v Hradci Králové
publication
Aldo-keto reductase 1C3 (AKR1C3): a missing piece of the puzzle in the dinaciclib interaction profile
2018 |
Farmaceutická fakulta v Hradci Králové
publication
Roscovitine and purvalanol A effectively reverse anthracycline resistance mediated by the activity of aldo-keto reductase 1C3 (AKR1C3): A promising therapeutic target for cancer treatment
2018 |
Farmaceutická fakulta v Hradci Králové
publication
Cloning, expression and purification of AKR1C3
Publikace bez příslušnosti k fakultě
publication
AKR1C3 as a potential target for the inhibitory effect of dietary flavonoids
Publikace bez příslušnosti k fakultě
publication
Reduction of anticancer drug doxorubicin by recombinant AKR1C3
Publikace bez příslušnosti k fakultě
publication
Role of AKR1C3 in metabolism of anticancer drug oracin
Publikace bez příslušnosti k fakultě
publication
AKR1C3 as a potential target for the inhibitory effect of dietary flavonoids
2009 |
Ústřední knihovna
publication
AKR1C3 as a potential target for the inhibitory effect of dietary flavonoids
2009 |
Farmaceutická fakulta v Hradci Králové
publication
Diet flavonoids inhibit specific aldo-keto reductase AKR1C3
Publikace bez příslušnosti k fakultě
publication
Reduction of anticancer drugs doxorubicin and oracin by recombinant AKR1C3
Publikace bez příslušnosti k fakultě
publication
Olaparib Synergizes the Anticancer Activity of Daunorubicin via Interaction with AKR1C3
2020 |
Farmaceutická fakulta v Hradci Králové
publication
AKR1C3 Inhibitory Potency of Naturally-occurring Amaryllidaceae Alkaloids of Different Structural Types
2017 |
Farmaceutická fakulta v Hradci Králové
publication
Optimization of HPLC technique for measurement of AKR1C3 activity
Publikace bez příslušnosti k fakultě
publication
Bruton's Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib Counteract Anthracycline Resistance in Cancer Cells Expressing AKR1C3
2020 |
Farmaceutická fakulta v Hradci Králové
publication
Inhibition of AKR1C3 human reductase activity by selected flavonoids and NSAID
Publikace bez příslušnosti k fakultě
publication
Inaktivace protinádorových léčiv doxorubicinu a oracinu vlivem aldo-ketoreduktasy (AKR) 1C3
2008 |
Ústřední knihovna
publication
Selective inhibition of aldo-keto reductase 1C3: a novel mechanism involved in midostaurin and daunorubicin synergism
2021 |
Farmaceutická fakulta v Hradci Králové
publication
Buparlisib is a novel inhibitor of daunorubicin reduction mediated by aldo-keto reductase 1C3
2019 |
Farmaceutická fakulta v Hradci Králové
publication
Isocitrate dehydrogenase 2 inhibitor enasidenib synergizes daunorubicin cytotoxicity by targeting aldo-keto reductase 1C3 and ATP-binding cassette transporters
2022 |
Farmaceutická fakulta v Hradci Králové
publication
Proteasome inhibitors MG-132 and bortezomib induce AKR1C1, AKR1C3, AKR1B1, and AKR1B10 in human colon cancer cell lines SW-480 and HT-29
2011 |
Farmaceutická fakulta v Hradci Králové
publication
Redukce doxorubicinu a oracinu a indukce karbonylreduktasy v lidských prsních nádorových buňkách MCF-7
2008 |
Ústřední knihovna
publication
Anthracycline resistance mediated by reductive metabolism in cancer cells: The role of aldo-keto reductase 1C3
2014 |
Farmaceutická fakulta v Hradci Králové
publication
Inactivation of the anticancer drugs doxorubicin and oracin by aldo-keto reductase (AKR) 1C3
2008 |
Farmaceutická fakulta v Hradci Králové
publication
Interactions of antileukemic drugs with daunorubicin reductases: could reductases affect the clinical efficacy of daunorubicin chemoregimens?
2020 |
Farmaceutická fakulta v Hradci Králové
publication
Bruton's Tyrosine Kinase Inhibitor Zanubrutinib Effectively Modulates Cancer Resistance by Inhibiting Anthracycline Metabolism and Efflux
2022 |
Farmaceutická fakulta v Hradci Králové
publication
Carbonyl reduction of warfarin: Identification and characterization of human warfarin reductases
2016 |
Farmaceutická fakulta v Hradci Králové
publication
Pharmacokinetic interactions of breast cancer chemotherapeutics with human doxorubicin reductases
2015 |
Farmaceutická fakulta v Hradci Králové
publication
Cyclin-dependent kinase inhibitors AZD5438 and R547 show potential for enhancing efficacy of daunorubicin-based anticancer therapy: Interaction with carbonyl-reducing enzymes and ABC transporters
2019 |
Farmaceutická fakulta v Hradci Králové
publication
In vitro metabolism of fenofibric acid by carbonyl reducing enzymes
2016 |
Farmaceutická fakulta v Hradci Králové